<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601027</url>
  </required_header>
  <id_info>
    <org_study_id>BRS0058</org_study_id>
    <secondary_id>34315</secondary_id>
    <nct_id>NCT02601027</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA</brief_title>
  <official_title>A Phase III Study of Pre-operative Transversus Abdominis Plane Blocks Using the Nimbus Ambulatory Infusion System in Patients Undergoing Abdominal Free Flap-based Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if using abdominal nerve blocks when patient
      undergo breast reconstruction can significantly decrease use of pain medications after
      reconstructive surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to determine if using abdominal nerve blocks when patient
      undergo breast reconstruction can significantly decrease use of pain medications after
      reconstructive surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Narcotic Usage</measure>
    <time_frame>48 hours</time_frame>
    <description>Total oral morphine equivalents of narcotic used in first 48 hours post-operatively after breast reconstruction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Score</measure>
    <time_frame>48 hours</time_frame>
    <description>Post-operative Pain Score is defined using Visual Analog Scale (VAS), a patient reported pain score on a scale of 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Anti-emetic Usage</measure>
    <time_frame>48 hours</time_frame>
    <description>Post-operative Anti-emetic Usage is defined as the total amount of IV ondansetron administered to a patient during the first 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>from midnight on POD, up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement</measure>
    <time_frame>from midnight on POD, up to 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 months post-operative</time_frame>
    <description>Quality of Life is defined as the calculated score from the BREAST-Q questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Breast - Female</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sham TAP catheter with saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of 0.125% bupivacaine through TAP catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine infusion</intervention_name>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetominophen</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAP catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Prior diagnosis or presumed diagnosis of breast cancer or undergoing prophylactic
             treatment.

          -  Greater than 18 years old.

          -  Female.

          -  Undergoing microsurgical breast reconstruction with abdominal free flap.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria

          -  True allergy to local anesthetics or opioids.

          -  History of addiction to narcotics within the last 24 months

          -  History of chronic pain on opioids within the last 24 months.

          -  Specific mental health issues such as schizophrenia or bipolar disorder.

          -  Patients who are pregnant.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon K. Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afaaf Shakir</last_name>
      <email>ashakir@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Gordon K. Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

